PMID- 23159026
OWN - NLM
STAT- MEDLINE
DCOM- 20130626
LR  - 20181202
IS  - 1873-4588 (Electronic)
IS  - 0892-1997 (Linking)
VI  - 27
IP  - 1
DP  - 2013 Jan
TI  - Oropharyngeal pH monitoring for laryngopharyngeal reflux: is it a reliable test 
      before therapy?
PG  - 84-9
LID - S0892-1997(12)00120-8 [pii]
LID - 10.1016/j.jvoice.2012.08.006 [doi]
AB  - OBJECTIVE: Current methods of measuring pharyngeal pH are problematic. The aim of 
      the study was to assess the ability of the oropharyngeal pH monitoring (Restech) 
      in predicting the response to proton pump inhibitor (PPI) therapy in patients 
      with gastroesophageal reflux disease-related laryngopharyngeal symptoms. STUDY 
      DESIGN: The study design is prospective and uncontrolled. METHODS: Twenty-two 
      consecutive naive patients with chronic laryngeal symptoms were enrolled. Reflux 
      symptom index, fibrolaryngoscopy, and 24-hour oropharyngeal pH monitoring were 
      performed. Both patients and laryngoscopist were blinded by the results of 
      Restech. All the patients were given a 3-month therapy with pantoprazole of 40mg 
      twice a day and then repeated both the reflux symptom index and 
      fibrolaryngoscopic evaluation. Patients were considered as responders if a 
      five-point decrease in symptom score was recorded. RESULTS: Thirteen of the 22 
      patients (59.1%) responded to therapy. Laryngoscopic findings did not correlate 
      with the clinical improvement after the 3 months of PPI. Nine patients (40.9%) 
      had a pathologic Restech study, and all resulted responsive to PPI; nine patients 
      (40.9%) with a negative Restech were nonresponsive to PPI, and four patients 
      (18.2%) despite a negative Restech resulted responsive to therapy. Responsive 
      patients showed both a higher oropharyngeal acid exposure in orthostatic position 
      and a higher Ryan score, compared with nonresponders (49.74+/-58.11 vs 2.12+/-0.0, 
      P=0.002). Considering responsiveness to medical therapy as the gold standard of 
      laryngopharyngeal reflux (LPR) for the diagnosis of LPR, Restech showed a 
      sensitivity of 69% and a specificity of 100%. CONCLUSIONS: The high specificity 
      and reasonable sensitivity of this technique make the Restech an interesting tool 
      before therapy of patients with pharyngoesophageal reflux.
CI  - Copyright (c) 2013 The Voice Foundation. Published by Mosby, Inc. All rights 
      reserved.
FAU - Vailati, Cristian
AU  - Vailati C
AD  - Division of Gastroenterology and Gastrointestinal Endoscopy, Vita-Salute San 
      Raffaele University, San Raffaele Scientific Institute, Milan, Italy.
FAU - Mazzoleni, Giorgia
AU  - Mazzoleni G
FAU - Bondi, Stefano
AU  - Bondi S
FAU - Bussi, Mario
AU  - Bussi M
FAU - Testoni, Pier Alberto
AU  - Testoni PA
FAU - Passaretti, Sandro
AU  - Passaretti S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20121115
PL  - United States
TA  - J Voice
JT  - Journal of voice : official journal of the Voice Foundation
JID - 8712262
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - D8TST4O562 (Pantoprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
MH  - Adult
MH  - *Esophageal pH Monitoring
MH  - Female
MH  - Humans
MH  - Laryngopharyngeal Reflux/*diagnosis/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pantoprazole
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/therapeutic use
EDAT- 2012/11/20 06:00
MHDA- 2013/06/28 06:00
CRDT- 2012/11/20 06:00
PHST- 2012/07/05 00:00 [received]
PHST- 2012/08/09 00:00 [accepted]
PHST- 2012/11/20 06:00 [entrez]
PHST- 2012/11/20 06:00 [pubmed]
PHST- 2013/06/28 06:00 [medline]
AID - S0892-1997(12)00120-8 [pii]
AID - 10.1016/j.jvoice.2012.08.006 [doi]
PST - ppublish
SO  - J Voice. 2013 Jan;27(1):84-9. doi: 10.1016/j.jvoice.2012.08.006. Epub 2012 Nov 
      15.